Canine Leptospirosis Outbreak in Japan

Jun Saeki and Aki Tanaka

Department of Animal Sciences, Tokyo University of Science, Tokyo, Japan. Department of Wildlife Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan

Canine leptospirosis was suspected in 11 dogs in Osaka Prefecture, Japan and 9 dogs died within a month, from October 12 to November 10, 2017. Eight of the dogs had been taken on walks along the same riverbed and 4 dogs lived in the same town. Logistic regression analysis between a comparative group and the incident cases group showed that the odds of leptospirosis infection was 13.3 times higher ($p = 0.044$) in the dogs taken on walks along the riverbed than in the dogs not being walked along the riverbed. It is suggesting that these walks had been a risk factor. Microscopic agglutination tests showed that antibody titers against *Leptospira interrogans* serovar **Australis** were 1:2,560 and 1:10,240 in 2 dogs. Therefore, *L. interrogans* serovar Australis was suspected to be the causative agent, for which no canine vaccine is available in Japan. These results suggested that *L. interrogans* serovar Australis can cause local outbreaks. The development of a canine vaccine against various serotypes might help reduce local infections. Leptospirosis is an important infectious disease of dogs and it is also a zoonotic disease.

**Keywords:** leptospirosis, outbreak, Australis, dog, zoonosis

**INTRODUCTION**

Leptospirosis is a common zoonotic disease caused by infection with the bacterium *Leptospira interrogans*, which has 24 serogroups and more than 250 known serovars (1–4). When infected with *L. interrogans*, animals may exhibit an acute course with symptoms such as jaundice, hemorrhage, and renal failure, or they might have few symptoms but continue shedding the bacteria (1–4). In some cases, animals shed the bacteria in their urine for several weeks to several years (2–4). Humans and dogs can be infected by direct or indirect contact with water and soil contaminated by the urine of wild rodents and other animals carrying the bacteria (2–4). In Japan, human infection with *L. interrogans* is categorized as a Class 4 infectious disease under the Act on the Prevention of Infectious Diseases and Medical Care for Patients with Infectious Diseases (the Infectious Diseases Control Law). In addition, the Act on Domestic Animal Infectious Diseases Control requires veterinarians to report dogs infected with *L. interrogans* serovars Pomona, Canicola, Icterohaemorrhagiae, Autumnalis, and Australis, *L. kirschneri* serovar Grippotyphosa, and *L. borgpetersenii* serovar Hardjo, as well as suspected cases. In October and November 2017, there was a series of notifications of suspected cases of canine leptospirosis based on the Act on Domestic Animal Infectious Diseases Control in Osaka Prefecture, Japan. An overview of these canine leptospirosis outbreak cases was previously reported (5). However, there have been few reports of community-acquired infections in dogs. Therefore, the aim of this study was to further analyze the outbreak and estimate the risk factors for infection.
METHODS

Cases Investigated
The study population included dogs with suspected canine leptospirosis and dogs that visited veterinary hospitals in the northern part of Osaka Prefecture from September to November 2017 for vaccinations or other symptoms not characteristic for leptospirosis, such as skin diseases. Medical records were retrospectively evaluated and reported suspected cases of canine leptospirosis were included for analysis. Obtained data included breed, sex, age, date of onset, symptoms, basis of diagnosis, prognosis, vaccination history, dog walking route, and outing history.

An observational study design was employed to evaluate factors associated with the suspected leptospirosis.

Statistical Analysis
The Shapiro–Wilk test was performed to evaluate the normality of the data. Logistic regression analysis was performed to evaluate the factors associated with suspected leptospirosis cases and breed, age, sex, vaccination history, type of vaccine, and history of walking along riverbeds. Stata/IC 16 (StataCorp LLC, College Station, Texas) was used for all analyses. For statistical inferences, two-sided hypothesis tests were used with a 5% significance level.

Microscopic Agglutination Test
Sera were obtained from six cases and were tested using the microscopic agglutination test (MAT) and a panel of seven reference serotypes, as indicated by the standard method described by the International Epizootic Office (OIE) Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2021 (6). Five serovars were used: L. interrogans serovars Canicola (L. Canicola), Australis (L. Australis), Copenhageni (L. Copenhageni), Autumnalis (L. Autumnalis), and Hebdomadis (L. Hebdomadis). The antibody titers for L. interrogans serovar Copenhageni were considered as those for L. interrogans serovar Icterohaemorrhagiae (L. Icterohaemorrhagiae) because both of them belong to the same serogroup.

RESULTS

Statistical Analysis
Characteristics of the study population are presented in Table 1. The study included 19 dogs who were vaccinated by eight veterinarians in October to November 2017. Eleven dogs (case No. 4, 5, 7, 9, 10, 11, 12, 14, 16, 17, and 19) with suspected canine leptospirosis, another eight dogs (case No. 1, 2, 3, 6, 8, 13, 15, and 18) were included as a comparative group that were brought to the hospital for vaccination or other symptoms not characteristic for leptospirosis, such as skin diseases. Age ranged from 1 to 13 years, and seven Dogs were male and 12 Dogs were female. Of the 11 dogs suspected to be infected, five dogs were diagnosed as having leptospirosis based on clinical symptoms or clinical course (case No. 5, 7, 14, 16, and 17), four dogs were IgM antibody positive (case No. 9, 10, 11, and 12), and two had Leptospira spp. DNA detected in the blood (case No. 19) and urine (case No. 4) was analyzed by polymerase chain reaction (PCR). All six dogs that had been vaccinated with a combination of two or three Leptospira spp. antigens died (case No. 4, 5, 12, 14, 16, and 19), including 4 dogs that had been vaccinated within 1 year (case No. 4, 5, 14, and 19). Whereas, neither of two recovered cases had been vaccinated with Leptospira spp. Antigens (case No. 7 and 11). Eight of the infected dogs died in the same city (case No. 4, 5, 9, 11, 12, 16, 17, and 19) and four dogs died within a 100-m radius of each other (case No. 9, 11, 12, and 17). In terms of outing history, seven of these eight dogs had been taken on walks along the same riverbed as their usual walking route (case No. 4, 5, 9, 11, 12, 16, and 19).

There were no significant associations of vaccination within 1 year, the presence of Leptospira spp. antigens in the vaccine, breed, age, or sex with the occurrence of suspected symptoms of leptospirosis. The odds of leptospirosis infection were 13.3 times higher in the dogs that had a history of being taken for walks along the riverbed than in the dogs not being walked along the riverbed ($p = 0.044$).

MAT
Antibody titers against Leptospira spp. antigens in six cases are shown in Table 2. MAT was able to be performed on six cases in which the veterinarians cooperated in providing samples.

A titer of 1/100 is taken as a positive titer by the International Epizootic Office (OIE) Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2021 (6). The definitive diagnosis of infection was set at an antibody titers of 1:800 or higher (2, 11). Notably, case No. 11 showed clinical signs of jaundice and hepatic failure, and the anti-L. Australis antibody titer was 1:10,240. Case No. 19 showed jaundice and renal failure, and the anti-L. Australis antibody titer was 1:2,560.

DISCUSSION

According to the Osaka Prefectural Livestock Hygiene Service Center, the number of canine leptospirosis cases reported in accordance with the law in Osaka Prefecture was five cases in 2014, five cases in 2015, and one case in 2016. The cases in the present study were considered to constitute an outbreak because the number of notifications was almost double that of previous years, with 11 cases reported within a month, from October 12 to November 10, 2017.

In dogs infected with Leptospira spp., bacteremia occurs within about 4 days of infection, and various clinical symptoms appear within about 7 days. After about 10 days of infection, antibody levels rise, and after about 2 weeks, the bacteria are excreted in the urine (4). Because the course of the disease depends on the antibody status of the individual (4), diagnoses in clinical cases should be made by selecting appropriate test methods, considering vaccination history and timing, and comprehensively evaluating clinical symptoms (2–4). In the present study, infection was confirmed in 7 cases by either MAT, PCR, or IgM antibody detection, but in three cases resulting in death due to acute progression, diagnosis was based on characteristic clinical symptoms. In another case, diagnosis was based on characteristic clinical symptoms and exclusion diagnosis.
| No. | Reported date | Breed      | Age (years)/sex | Address            | Onset date | Symptoms | Purpose of visit | Evidence of diagnosis | Prognosis | Condition | Vaccination history$^a$ (year/month) | Walk to the riverbed | Death date | Visit date |
|-----|---------------|------------|----------------|--------------------|------------|----------|-----------------|------------------------|-----------|-----------|-------------------------------------|----------------------|------------|------------|
| 1   | –             | Toy Poodle | 4 y/F          | 4, K-cho, J-city   | –          | Panniculitis | –               | Good                   | 6 combination vaccine (2014) | Yes       | –         | 9/22      |
| 2   | –             | Bichon Frise | 1/M           | 2, K-town, J-city  | –          | Flea parasites | –               | Good                   | 5 combination vaccine (2017) | No        | –         | 9/26      |
| 3   | –             | Shiba      | 6/F            | 4, K-town, J-city  | –          | Combination vaccination | –               | Good                   | 5 combination vaccine (2017) | Yes       | –         | 9/26      |
| 4   | 10/16         | Border Collie | 3/F          | 1, K-town, J-city  | 9/Late     | Jaundice, DIC | IgM (-) Urine PCR (+) | Death                  | 8 Combination vaccine (2016) | Yes       | Unknown   | 9/late    |
| 5   | 10/16         | Border Collie | 10/M         | 1, K-town, J-city  | 9/late     | Jaundice, DIC | Clinical symptoms IgM (-) Urine PCR (-) | Death                  | 8 Combination vaccine (2016) | Yes       | Unknown   | 9/late    |
| 6   | –             | Shih Tzu    | 9/M            | 1, S-town, J-city  | –          | Dermatitis | –               | Good                   | Unknown   | No        | 10/3      |
| 7   | 10/18         | German Shepherd | 5/M         | 5, M-town, L-city  | 10/2       | Jaundice, Hepatic failure Renal failure | Clinical symptoms Urine PCR (-) | Recovery              | 6 Combination vaccine (2017/5) | Yes       | –         | 10/5      |
| 8   | –             | Papillon    | 1/F            | 3, K-town, J-city  | –          | Rabies vaccination | –               | Good                   | 6 Combination vaccine (2016) | No        | –         | 10/6      |
| 9   | 10/15         | Mongrel     | 4/F            | 1, N-town, J-city  | 10/8       | Severe, Acute death | IgM (+) | Death                  | Unvaccinated               | Yes       | 10/11     | 10/11     |
| 10  | 10/18         | Bulldog    | 6/F            | 2, Q-town, P-city  | 10/8       | Hepatic dysfunction | IgM (+) Urine PCR (-) | Death                  | Unvaccinated               | No        | Unknown   | 10/12     |
| 11  | 10/12         | Mongrel     | 5/F            | 1, N-town, J-city  | 10/9       | Jaundice, Hepatic failure | IgM (+) Urine PCR (-) | Recovery              | 5 Combination vaccine (2016/9) | Yes       | –         | 10/11     |
| 12  | 10/19         | Mongrel     | 13/F           | 1, N-town, J-city  | 10/10      | Pyrexia, Jaundice, Renal failure | IgM (+) | Death                  | 9 Combination vaccine (2015/12) | Yes       | Unknown   | 10/13     |
| 13  | –             | Shiba      | 4/F            | 3, K-town, J-city  | –          | Rabies vaccination | –               | Good                   | Unvaccinated               | Unknown   | –         | 10/14     |

(Continued)
| No. | Reported date | Breed                  | Age (years)/sex | Addressa | Onset date | Symptoms Purpose of visit | Evidence of diagnosis | Prognosis Condition | Vaccination historyb/year/month | Walk to the riverbed | Death date | Visit date |
|-----|---------------|------------------------|-----------------|----------|------------|---------------------------|----------------------|--------------------|---------------------------------|---------------------|------------|------------|
| 14  | 11/10         | Miniature Schnauzer    | 8/M             | 2, S-town, T-ward, R-city | 10/15      | Severe, Acute death       | Clinical progress    | Death               | 8 Combination vaccine (2016/7) | Unknown            | 10/18      | 10/18      |
| 15  |               | Miniature Dachshund    | 5/F             | 3, K-town, J-city          | –          | Combination vaccination   | –                    | Good                | 6 Combination vaccine (2017)  | No                  | –          | 10/18      |
| 16  | 10/29         | Toy Poodle             | 10/M            | 1, K-town, J-city          | 10/18      | Jaundice, Renal failure  | Clinical symptoms Urine/Blood PCR (–) | Death               | 9 combination vaccine (2015/5) | Yes                | 10/23      | 10/20      |
| 17  | 10/26         | Miniature Schnauzer    | 8/M             | 1, N-town, J-city          | 10/22      | Hepatic failure Renal failure, thrombopenia | Clinical symptoms | Death               | Unvaccinated | Unknown            | 10/23      | 10/23      |
| 18  |               | Mongrel                | 11/F            | 1, N-town, J-city          | –          | Home visit (cohabitation dog) | –                    | Good                | 5 combination vaccine (2013)  | Yes                | –          | 10/23      |
| 19  | 11/9          | Mix                    | 11/F            | 1, R-town, J-city          | 11/1       | Jaundice, Renal failure  | Urine PCR (–) Blood PCR (+)    | Death               | 9 combination vaccine (2016/9) | Yes                | 11/4       | 11/1       |

aCity and town names are not shown for privacy and anonymity.
b5 and 6 combination vaccines: did not contain Leptospira spp. antigens; 8 combination vaccine: including serovar Icterohaemorrhagiae and serovar Canicola antigens; 9 combination vaccine: including serovar Copenhageni, serovar Canicola, and serovar Hebdomadis antigens.

DIC, disseminate intravascular coagulation; F, female; M, male; PCR, polymerase chain reaction.
In diagnosis by MAT, paired sera are used immediately after and 10 to 14 days after disease onset, and if the antibody titer increases more than 4-fold, infection with the suspected serovar is diagnosed (2–4). However, in many cases in the present study, progress was acute and paired sera collection was difficult, so the diagnosis was made using a single serum sample. Many cases of acute leptospirosis die within 2–4 days after disease onset, before IgG antibodies rise (2–4). The IgM antibody test can detect leptospirosis at the early stage of infection because IgM antibodies increase within a bout 3–7 days after infection before decreasing (2–4). The IgM antibody test can detect antibodies against L. Canicola, L. Icterohaemorrhagiae, L. Hebdomadis, L. Autumnalis, L. Australis detected in the present study. This indicates that testing for IgM antibodies is as useful as testing for IgG antibodies for early diagnosis.

| No. | Antigens | Antibody titers |
|-----|----------|----------------|
| 11  | Lc<1:10  | Li 1:160       |
| 12  | Lc<1:10  | Li 1:40        |
| 14  | Lc<1:10  | Li 1:320       |
| 16  | Lc<1:10  | Li 1:40        |
| 17  | Lc<1:10  | Li<1:10       |
| 19  | Lc<1:10  | Li 1:80        |

In the present study, factors associated with an outbreak of canine leptospirosis were evaluated.

L. Hebdomadis has been documented as the most common cause of canine leptospirosis in Japan, accounting for 53.3% of all reported cases (11). Although vaccination is reported to be effective in preventing onset and reducing the severity of canine leptospirosis (12), effectiveness is considered serovar-specific (13). Currently, the Leptospira spp. canine vaccine available in Japan contains only L. Canicola, L. Icterohaemorrhagiae, L. Hebdomadis, L. Interrogans serovars Pomona and L. Kirschneri serovar Grippoparphyxis antigens, and does not contain the antigens of L. Australis detected in the present study. This might explain why some dogs died in this outbreak despite being vaccinated against Leptospira spp. There are known to be regional differences in the detected serovars (3, 14, 15). Because L. Australis has been reported to be the second-highest detected serovar (20.3%) after L. Hebdomadis in dogs in Japan (14), it is necessary to develop a vaccine containing antigens of this serovar. It is also desirable to develop vaccines in other countries and regions according to the outbreak situation.

Limitation of Study

Because this was a field survey of spontaneous cases, the number of cases was small and most of the dogs were not available for a long term follow up, some of the dogs died during the study period due to the illness. In addition, we were not able to obtain the complete information on the cases we evaluated.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article-supplementary material, further inquiries can be directed to the corresponding author.
AUTHOR CONTRIBUTIONS
JS was involved in the study design and data interpretation. AT was involved in the data analysis. Both authors critically revised the report, commented on drafts of the manuscript, and approved the final report.

ACKNOWLEDGMENTS
We would like to express our deepest gratitude to the Animal Protection and Livestock Division, Osaka Prefecture and to the veterinarians who cooperated in the interviews and in the epidemiological survey. We also thank Kyoto Biken Laboratories, Inc. for their cooperation in the testing.

REFERENCES
1. Levett PN. Leptospirosis. Clin Microbiol Rev. (2011) 14:296–326. doi: 10.1128/CMR.14.2.296-326.2001
2. Sykes JE, Hatmann K, Lunn KF, Moore GE, Stoddard RA, Goldstein RE. 2010 ACVIM small animal consensus statement on leptospirosis: diagnosis, epidemiology, treatment, and prevention. J Vet Int Med. (2011) 25:1–13. doi: 10.1111/j.1939-1676.2010.0654.x
3. Schuller S, Francye T, Hartmann K, Hugonnard M, Kohn B, Nally JE, et al. European consensus statement on leptospirosis in dogs and cats. J Small Anim Pract. (2015) 56:159–79. doi: 10.1111/jsap.12328
4. Green CE, Sykes JE, Moore GE, Goldstein RE, Schultz RD. Leptospirosis. In: Green CE, editor. Infectious Diseases of the Dog and Cat. 4th ed. Toronto, ON: Elsevier Inc. (2012). p. 431–47.
5. Saeki J, Kitahara C. Canine leptospirosis outbreak in Osaka. J Jpn Vet Med Assoc. (2019) 72:167–71. doi: 10.12935/jvma.72.167
6. International Epizootic Office Manual of Diagnostic Tests and Vaccines for Terrrestrial Animals. Chapter 3.1.12 Leptospirosis. Paris: OIE (2021).
7. Branger C, Blanchard B, Fillonneau C, Suard I, Aviat F, Chevallier B, et al. Polymerase chain reaction assay specific for pathogenic Leptospira based on the gene hap1 encoding the hemolysis-associated protein-1. FEMS Microbiol Lett. (2005) 243:437–45. doi: 10.1016/j.femsle.2005.01.007
8. Ikeda T, Asano M, Matoba Y, Abe G. Present status of invasive alien raccoon and its impact in Japan. Glob Environ Res. (2004) 8:125–31.
9. Prescott J. Canine leptospirosis in Canada: a veterinarian’s perspective. Can Med Assoc J. (2008) 178:397–8. doi: 10.1503/cmaj.071092
10. Saeki J, Nakashima H, Masubuchi K, Matsubayashi M, Furuya M, Tani H, et al. A serological survey of Leptospira spp. antibodies in wild raccoons (Procyon lotor) in Osaka, Japan. Asian J Anim Vet Adv. (2016) 11:258–62. doi: 10.3923/ajava.2016.25.8.262
11. Koizumi N, Mizutani M, Akachi S, Okano S, Yamamoto S, Horikawa K, et al. Molecular and serological investigation of Leptospira and leptospirosis in dogs in Japan. J Med Microbiol. (2013) 62:630–6. doi: 10.1099/jmm.0.050039-0
12. Andre-Fontaine G, Triger L. MAT cross-reactions or vaccine cross-protection: retrospective study of 863 leptospirosis canine cases. Heliyon. (2018) 4:e00869. doi: 10.1016/j.heliyon.2018.e00869
13. Koizumi N, Watanabe H. Leptospirosis vaccines: past, present, and future. J Postgrad Med. (2005) 51:210–4.
14. Akuzawa M, Oishi A, Fuchiku S, Deguchi E, Misumi K, Sakamoto H, et al. Survey of the Leptospira antibody from dogs in 6 regions of Japan. J Jpn Vet Med Assoc. (1999) 52:780–3. doi: 10.12935/jvma1951.52.780
15. Takeda M, Konishi M, Shiono M, Iida Y, Nagata H, Katsura S, et al. Prevalence of Leptospira antibodies among stray dogs in Osaka, Japan. J Jpn Vet Med Assoc. (2004) 57:809–12. doi: 10.12935/jvma1951.57.809

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Saeki and Tanaka. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.